CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 40 target
Drug / intervention
Inotuzumab Ozogamicinbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03441061
NCT03441061Phase 2ActiveOn TrackUpdated 4mo ago
CompareCT.gov

Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

M.D. Anderson Cancer Center·interventional·Posted Feb 22, 2018·Updated Feb 17, 2026

In Brief

A Phase 2 clinical trial evaluating Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia and 2 related conditions. Active but no longer recruiting, targeting 40 participants across 1 site.

Detailed Summary

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a toxic agent called ozogamicin. Inotuzumab ozogamicin attaches to B cell-specific CD22 cancer cells in a targeted way and kills them.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2Active
2018201920202021202220232024202520262027
First PostedFeb 22, 2018
Enrollment StartFeb 15, 2018
Primary CompletionFeb 28, 2027
TodayJul 1, 2026
Enrollment to primary: 9.0 yearsPosted 8.4 years agoPrimary completion in 8 months

Interventions

Inotuzumab Ozogamicinbiological

Given IV